Literature DB >> 20167420

Abrogation of Akt signaling by Isobavachalcone contributes to its anti-proliferative effects towards human cancer cells.

Hui Jing1, Xinglu Zhou, Xiaowu Dong, Ji Cao, Hong Zhu, Jianshu Lou, Yongzhou Hu, Qiaojun He, Bo Yang.   

Abstract

Akt signaling pathway has attracted much attention as a promising target for cancer therapeutics. Herein, we report that Isobavachalcone (IBC), a natural chalcone, potently abrogates Akt signaling and exerts anti-proliferative effects on several human cancer cell lines. Modeling results from the Sybyl/FlexiDock program suggest that IBC potentially binds to the ATP-binding pocket of Akt, which is confirmed by the observations that IBC inhibits Akt1 kinase in vitro. Further studies reveal that IBC significantly abates Akt phosphorylation at Ser-473 and Akt kinase activity in cells, which subsequently leads to inhibition of Akt downstream substrates and evokes significant levels of apoptosis associated with mitochondria pathway. Copyright 2010 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20167420     DOI: 10.1016/j.canlet.2010.01.035

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  27 in total

Review 1.  Isobavachalcone: an overview.

Authors:  Victor Kuete; Louis P Sandjo
Journal:  Chin J Integr Med       Date:  2012-07-07       Impact factor: 1.978

Review 2.  The role of chalcones in suppression of NF-κB-mediated inflammation and cancer.

Authors:  Vivek R Yadav; Sahdeo Prasad; Bokyung Sung; Bharat B Aggarwal
Journal:  Int Immunopharmacol       Date:  2010-12-22       Impact factor: 4.932

Review 3.  Potential of Central, Eastern and Western Africa Medicinal Plants for Cancer Therapy: Spotlight on Resistant Cells and Molecular Targets.

Authors:  Armelle T Mbaveng; Victor Kuete; Thomas Efferth
Journal:  Front Pharmacol       Date:  2017-06-02       Impact factor: 5.810

4.  [Isobavachalcone induces cell death through multiple pathways in human breast cancer MCF-7 cells].

Authors:  Y Zhang; M Gao; M Zhu; H Li; T Ma; C Wu
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2022-06-20

5.  Cyclic chalcone analogue KRP6 as a potent modulator of cell proliferation: an in vitro study in HUVECs.

Authors:  Lenka Ivanova; Lenka Varinska; Martina Pilatova; Peter Gal; Peter Solar; Pal Perjesi; Karel Smetana; Alexander Ostro; Jan Mojzis
Journal:  Mol Biol Rep       Date:  2013-05-11       Impact factor: 2.316

6.  Cameroonian medicinal plants: pharmacology and derived natural products.

Authors:  Victor Kuete; Thomas Efferth
Journal:  Front Pharmacol       Date:  2010-10-25       Impact factor: 5.810

7.  Stressing the ubiquitin-proteasome system without 20S proteolytic inhibition selectively kills cervical cancer cells.

Authors:  Ravi K Anchoori; Saeed R Khan; Thanasak Sueblinvong; Alicia Felthauser; Yoshie Iizuka; Riccardo Gavioli; Federica Destro; Rachel Isaksson Vogel; Shiwen Peng; Richard B S Roden; Martina Bazzaro
Journal:  PLoS One       Date:  2011-08-31       Impact factor: 3.240

8.  A new synthetic chalcone derivative, 2-hydroxy-3',5,5'-trimethoxychalcone (DK-139), suppresses the Toll-like receptor 4-mediated inflammatory response through inhibition of the Akt/NF-κB pathway in BV2 microglial cells.

Authors:  Young Han Lee; Seung-Hyun Jeon; Se Hyun Kim; Changyoun Kim; Seung-Jae Lee; Dongsoo Koh; Yoongho Lim; Kyooseob Ha; Soon Young Shin
Journal:  Exp Mol Med       Date:  2012-06-30       Impact factor: 8.718

9.  Targeting death receptor TRAIL-R2 by chalcones for TRAIL-induced apoptosis in cancer cells.

Authors:  Ewelina Szliszka; Dagmara Jaworska; Małgorzata Ksek; Zenon P Czuba; Wojciech Król
Journal:  Int J Mol Sci       Date:  2012-11-20       Impact factor: 5.923

10.  An update on antitumor activity of naturally occurring chalcones.

Authors:  En-Hui Zhang; Ru-Feng Wang; Shu-Zhen Guo; Bin Liu
Journal:  Evid Based Complement Alternat Med       Date:  2013-04-17       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.